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Objectives: The aim of this study was to assess incidence, time frame, and outcome of “Coverage with Evidence Development” (CED) decisions in the Swiss Basic Health Insurance
scheme.
Methods: Analysis of all controversial medical technologies submitted to review by the Swiss Federal Office of Public Health (FOPH) from 1996 to 2012 with focus on decisions with
constraints. Description of types of technology, type of initial decision, duration of evaluation period, final decision, and search for potential factors associated with changes over time.
Results: Forty-five (37.5 percent) of 120 controversial health technologies were classified as “yes, in evaluation, reimbursed” for a certain period of time and thirty-five (29.2
percent) as “no, in evaluation, not reimbursed” by the Federal Department of Home Affairs from 1996 to 2012. The rate of CED decisions ranged between zero and nine per year
and was influenced by type of technology and calendar year. Forty-four of forty-five decisions were subject to further restrictions, to a “center or a specialist” (76 percent),
“indications” (49 percent), “registry” (31 percent), or “other” (49 percent). The time to a final decision ranged from 1.5 to 11 years (median, 6 years). No factors associated
with initial decision and final outcome could be identified.
Conclusions: CED as a reality in Switzerland might have enabled patients to obtain access to promising technologies early in their life cycle. CED might have acted as a trigger to a
successful implementation of a comprehensive national registry. The lack of qualitative data stresses the urgent need for evaluation of the HTA decisions and their impact on patient
outcome and costs.
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Lack of evidence is one of the major obstacles to ensuring
timely access to new medical technologies. Decisions on their
adoption or coverage by any health care system should be based
on sufficient and reproducible data. “Coverage with Evidence
Development” (CED) is an approach that aims to bridge this
gap and to allow for early adoption of pharmaceuticals, med-
ical procedures and medical devices for a limited period of
time, and under explicit restricting conditions. This policy is
applied if novel medical technologies are promising yet con-
troversial or where additional evidence is required to make an
informed decision. One of the most interesting aspects of CED
is that it integrates HTA into decision making, allowing direct
“implementation” of HTA results into the technology appraisal
process.
The name CED was coined in the United States in 2005
by the Centers for Medicare and Medicaid Services (CMS) (1).
The authors thank Helen Baldomero and Swiss Blood Stem Cells for providing data from the
registry on hematopoietic stem cell transplants in Switzerland as well as Emin Aghayev and
Christoph Roeder for providing data from the Swiss spine registry. Thanks are also due to Rafael
Plessow for help with revising the manuscript and to Paul Kelly for proof reading. Funding: The
study was in part supported by a grant of the Bangerter Foundation.
The concept as such, however, existed before this and can vary
according to country or reimbursement system. It carries dif-
ferent names in other jurisdictions such as “Only in Research”
(United Kingdom), “Still in Research” (France), “Interim Fund-
ing” (Australia), “Conditionally Funded Field Evaluation” (On-
tario), or “Monitored Use” (Spain) (2). In 2008 the European
network for Health Technology Assessment (EUnetHTA) de-
veloped a special toolkit for monitoring the development of
emerging technologies and refers to these mechanisms as “Ac-
cess with Evidence Generation.”
Principles of good practice for CED were developed at the
so-called Banff Summit and published as a consensus statement.
They call for transparency, clarity, scientific rigor, appropriate-
ness and independence from vested interests (3). Academic
interest to better understand the functioning and the implica-
tions of CED has grown in line with the dissemination of the
concept (4;5). Incidentally, a clear sign of the relevance of the
subject is the establishment of a special “Interest Sub-Group on
Conditional Coverage and Evidence Development for Promis-
ing Technologies” by the international HTA organization HTAi,
with 250 members at the end of 2012.
Switzerland, where this concept was adopted by the Federal
Office of Public Health (FOPH; previously Office of Social
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Security) as early as 1996 (6), presents a particularly remarkable
example of CED in the area of nondrug technologies.
The documentation accompanying the application for cov-
erage of new and controversial technologies has been supported
and regulated since then in a series of further guidelines (7).
However, little is known about the implementation and the out-
come of the Swiss program.
Regulation of CED for Medical Procedures in Switzerland
Since 1996, when a new Federal Law on Sickness Insurance
came into force, all residents have been covered by basic health
insurance. In the Procedures Ordinance of January 1st 1996, the
insurance scheme accepted for the first time a series of medical
technologies for coverage which were novel and promising, but
for which existing evidence was incomplete. Among the first
technologies denoted “in evaluation” were five different tech-
nologies for the measurement of mineral bone density within a
multi-center study. The decision “Yes, in evaluation” made the
procedure obligatory for reimbursement by the health insurers.
In principle, all medical services and procedures that are
effective, appropriate and cost-effective are covered by social
health insurance in Switzerland. This means that Swiss physi-
cians and hospitals enjoy the so-called “principle of trust” unless
challenged by anyone with a legitimate interest, for example, a
health insurance provider. In such a case, the contested medical
service or procedure goes through an HTA process and its out-
comes are published in the appendix of the relevant procedures
ordinance. Thus, there is only a negative and conditional list
for medical services and procedures (including diagnostics and
devices) in place.
A potentially controversial medical service has to be re-
ported to the Federal Office of Public Health (FOPH), which is
responsible for, among other things, the supervision of the ben-
efit basket. In a first step, the FOPH consults the Swiss health
insurer’s association and the Swiss medical association. If this
first rough assessment of a medical service by the FOPH judges
it to be undisputed, it is reimbursed. Otherwise, it goes into a
structured technology appraisal process (8).
In this latter case, the provider or the manufacturer has to
submit full documentation of the available evidence on effec-
tiveness (including a systematic review), appropriateness and
cost-effectiveness for obligatory coverage of the specific med-
ical technology under the statutory health insurance scheme.
The FOPH then checks the submission for completeness and
writes a summary including critical issues. All information on
the case is assembled in a dossier which is then handed over
to the Federal Commission for Medical Benefits and Principles
(FCMBP/ELGK) for appraisal.
The commission consists of eighteen representatives of
health insurers, the medical profession, patient organizations,
hospitals, industry, ethics etc., and is appointed by the Fed-
eral Council (Swiss government). Its mandate is to examine the
effectiveness, appropriateness and efficiency of the controver-
sial procedure and to generate a substantiated recommendation
for the decision-making body, which is the Federal Department
of Home Affairs. The recommendation or decision can be one
of four categories: “Yes” or “No,” “Yes, in evaluation” or “No,
in evaluation” (the latter option was discontinued after 2004).
The decision “Yes, in evaluation” can be linked to restrictions
to specific centers or medical specialists, to specific indications,
or can presuppose additional requirements. The reimbursement
can be combined with the obligation to keep a patient-based
registry.
“Yes” and “Yes, in evaluation” mean obligatory coverage of
the procedure, whereas “No” and “No, in evaluation” mean no
reimbursement, and further evidence development will not be
compensated. The discussions within the appraisal commission
are not made public. Only the final decisions and the conditions
for approval are published in the appendix of the Procedures
Ordinance, which is updated at least annually.
This study aims to pursue the number and type of technolo-
gies accepted under restraint in Switzerland in the 17 years from
1996 to 2012, and to examine the duration of evaluation and its
relation to the final decision. It further aims to analyze the pro-
cess of decision making in the course of adoption or refusal of
technologies under conditional approval. Finally, it intends to
present the type and frequency of restrictions related to tech-
nologies under evaluationwith special emphasis on the outcome
of explicitly required registries for selected procedures.
METHODS
Study Design
This is a retrospective analysis of all controversial health tech-
nologies submitted for decisions by the Department of Home
Affairs from 1996 to 2012. They were grouped according to the
four categories “yes,” “yes, in evaluation,” “no, in evaluation,”
or “no”; specific focus was placed on decisions for reimburse-
ment under constraints.
Data Collection
All information was obtained from the appendix of the Pro-
cedures Ordinance, which contains the list of all controversial
health technologies since 1996. The Procedures Ordinance is
updated annually.
For all cases with “yes, in evaluation” and “no, in evalua-
tion” additional information was collected: type of technology,
date of initial decision, end and duration of evaluation period,
prolongation of the evaluation period if applicable, specific con-
ditions of evaluation if applicable, and final decision.
An in-depth analysis was performed for two technologies
where registries were required: spine surgery and hematopoietic
stem cell transplantation.
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Table 1. Number of Medical Technologies in CED Regime by Category
Diagnostic Medical Surgical Transplan- Radiological Alternative Share of
Procedures Interventions Interventions tations Interventions Miscellaneous Medicine Total Total
Yes, in evaluation 10 0 7 6 4 8 10 45 100%
Restricted to center or specialist 8 6 4 3 3 10 34 76%
Restricted indications 3 5 5 2 7 22 49%
Registry explicitly required 5 4 1 4 14 31%
Additional requirement 9 2 5 3 3 22 49%
No, in evaluation 3 5 5 10 6 6 35 100%
Restricted to center or specialist 3 3 9%
Restricted indications 3 1 4 11%
Registry explicitly required 3 3 9%
Additional requirement 3 3 9%
Total 13 5 12 16 10 14 10 80
Share of Total 16.30% 6.30% 15% 20% 12.50% 17.50% 12.50% 100%
Statistical Analysis
Descriptive statistics were used. Time to evaluation was as-
sessedwithmodified cumulative incidence plots. In otherwords,
the probabilities of the two potential final outcomes (“yes” /
“no”) are displayed in two cumulative incidence functions over
the duration of evaluation. To improve the interpretability, the
incidence function for a “final no” has been replaced by one
minus the probability of a “final no.” Hence, the difference
between these two curves represents the probability that the
decision maker has not yet come to a final decision, that is,
these cases still await approval or rejection. The applied estima-
tion method of these functions takes into consideration the fact
that some of the observations are censored, and that there is a
competing outcome (9). The computation has been done by the
Package “cmprsk” (Version 2.2–2 by Bob Gray) in the R system
(10). To test for homogeneity in a two-way contingency table
we use Pearson’s Chi-squared test as described, for example, in
Agresti (11). The test is performed using the function chisq.test
in the R core system.
RESULTS
Use and Incidence of CED in Switzerland
A total of 120 controversial health technologies were evaluated
and decided upon by the Federal Department of Home Affairs
from 1996 to 2012. Of these, a total of forty-five technolo-
gies (37.5 percent) were classified “yes, in evaluation” and fell,
therefore, under the regime of CED for a certain period of time
(Table 1). Diagnostic procedures (n = 10) and surgical inter-
ventions (n = 7) were the most frequent technologies in the
“yes, in evaluation” category. Alternative medicine holds the
same position (n = 10), which might be somewhat surprising.
This local peculiarity in Switzerland requires some explana-
tion. Several methods of alternative medicine were set under
the CED regime from 1999 until 2005. Based on a large evalu-
ation program the responsible minister took a “no” decision for
most of those methods at the expiry of the evaluation period.
After a popular referendum in 2008 in favor of the use of com-
plementary medicine in the Swiss health system, five methods
of complementary medicine were again listed as “yes, in evalu-
ation” again in 2012 for another 5 years. In 2017, a re-appraisal
will have to be made.
The method of CED was introduced as early as 1996 and
maintained throughout the whole evaluation period. There was
an apparent trend toward an increase up to the year 2003 fol-
lowed by a decline. Until the year 2002, each year roughly four
new technologies fell under the regime of CED (“yes, in eval-
uation”). From 2003 onward, this number fell to an average of
just a little over one technology per year.
A total of thirty-five technologies (29.2 percent) of the 120
technologies were classified “no, in evaluation” during the same
period of time (Table 1). The most frequent technologies in the
“no, in evaluation” category were transplants (n = 10) followed
by radiological (n= 6) interventions. This category was initially
introduced to signal to the providers of those health technolo-
gies that they had a realistic chance to get reimbursement at a
later stage if they could provide better evidence. Due to the fact
that no reimbursement was provided for technologies in this cat-
egory, it was difficult for the authorities to monitor and enforce
the necessary evidence-generation. Only two of these thirty-five
decisions were, upon re-evaluation, turned into “yes, in evalu-
ation.” Both relate to hematopoietic stem cell transplants for
autoimmune diseases. Thus, the category “no, in evaluation”
was abandoned in 2004, although this was never officially com-
municated. Since that year, no new such decision has beenmade.
Some of the technologies, however, that were classified “no, in
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Figure 1. Longitudinal sequence of the forty-five medical technologies in the category “yes, in evaluation.”
evaluation” before that year were still listed in the appendix of
the procedure ordinance with that label in the year 2013.
Restrictions
Forty-four of forty-five procedures in the CED regime are sub-
ject to further restrictions. Table 1 shows that these can be “re-
strictions to a center or a specialist” (34; 76 percent technolo-
gies), “restricted indications” (22; 49 percent technologies.),
“registry explicitly required” (14; 31 percent technologies), or
“additional requirements” (22; 49 percent technologies). Alto-
gether, for fourteen of forty-five interventions, a registry was
explicitly required. It is of interest to note that this additional
request primarily related to surgical interventions (5 of 7) and
transplants (4 of 6).
Outcome of Decisions “Yes, in Evaluation”
The evaluation time ranged from 1.5 years to 11 years. Mean
evaluation time for the initial evaluation period without prolon-
gation was 4.5 years (median 5 years) and 5.8 years (median
6 years) for the total evaluation period including prolongation.
Figure 1 shows a longitudinal sequence of the forty-five medi-
cal technologies in the category “yes, in evaluation.” The graph
also shows that the instrument was used more frequently before
2004 than thereafter.
For nineteen of the forty-five decisions (42 percent), the
final outcome was “yes,” for twelve (27 percent) “no.” Three
(7 percent) decisions were downgraded to “no, in evaluation.”
Eleven decisions (24 percent) still remain pending. Figure 2
illustrates the two cumulative incidence functions over the eval-
uation time in years for the thirty-two technologies with a final
decision until 2012. Most decisions are made after 3 to 7 years.
Registries
Registries are one of the additional restrictions under the CED
regime “yes, in evaluation.” The following examples are pre-
sented to illustrate the use of this tool in conditional coverage
in Switzerland.
Example 1: Reimbursement Decisions for Allogeneic Hematopoietic Stem Cell
Transplantation
Hematopoetic stem cell transplantation (HSCT) has a long-
standing tradition in Switzerland and was introduced in the
early 1970s when the procedure was still a challenging medical
intervention (12). Still, the key indications—leukemia, aplastic
anemia, and immunodeficiency—were listed in the Procedures
Ordinance early on. The introduction of the new law in 1996
coincided with a large expansion of indications, donor type and
stem cell source for HSCT worldwide. In contrast, scientific in-
formation on effectiveness and cost-effectiveness was lacking;
the procedure was primarily driven by expectations as best illus-
trated by the massive transient expansion of autologous HSCT
for breast cancer (13). However, in 1996, only Lymphoma was
added to the Procedures Ordinance as a novel indication with
“yes, in evaluation” and the establishment of a registry was re-
quested. The registry was established by the Swiss Transplant
Working Group Blood and Marrow Transplantation STABMT
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 30:3, 2014 256
https://doi.org/10.1017/S0266462314000233
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 18:57:58, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
Coverage with Evidence Development in Switzerland
0 2 4 6 8 10
0.0
0.2
0.4
0.6
0.8
1.0
Time to Decision [in Years]
Es
tim
at
ed
 
Pr
ob
ab
ilit
y
1 - (probability of final NO)
probability of final YES
FINAL DECISIONS FOR "Yes, in evaluation" 1996 - 2012
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and was based on the reporting structure of the European Group
for Blood and Marrow Transplantation EBMT (14). It was de-
clared mandatory for all STABMT members for all transplants,
including those with a “yes” and for those congenital disor-
ders paid for by the disability insurance and financed initially
by means of the mandatory STABMT membership fee. The
Procedures Ordinance was revised twice, in 2001 and 2008,
with extensions of indications and changes in categories. In
addition, all teams performing HSCT were obliged to fulfill a
quality management program and to be accredited by the Joint
Accreditation Committee ISHAGE Europe and EBMT JACIE
(15). Reimbursement of the procedure was linked to JACIE ac-
creditation. The registry was maintained. With the introduction
of the Federal Transplantation Act in 2004, Swiss Blood Stem
Cells obtained the official mandate in Switzerland for stem cell
transplantation and has overseen the registry since then. All four
teams performing allogeneic HSCT and all six teams perform-
ing autologousHSCT are currently accredited by JACIE (16;17)
and the Swiss registry collects data on all HSCT performed in
Switzerland. Outcome data are regularly published and data are
shared with the EBMT and the Worldwide Network of Blood
and Marrow Transplantation WBMT (18;19).
Table 2 shows the development of HSCT in Switzerland
over the three different time periods. Numbers of HSCT in-
creased over the years from 338 procedures per year in the first
period to 429 in the second and to 506 HSCT per year for the
period from 2008 to 2011. The proportion of procedures with a
“yes” or “yes, in evaluation” increased over time from 26 per-
cent and 22 percent respectively to 67 percent and 29 percent
respectively, by contrast, the number of procedures with “no,”
“no, in evaluation” and “not listed” steadily declined from a
total of 50 percent to just 1 percent in the last period. Of note,
approximately 2 percent of all HSCT in Switzerland, mainly
for congenital disorders, are covered by the disability insurance
scheme. Applying the Chi-squared test for homogeneity in the
observed frequencies of the categories “yes,” “yes, in evalua-
tion” and “no” along the three time periods, we see that the
frequencies of the categories are changing over time in a statis-
tically significant way (the value of the test statistic is 2353.9
and the corresponding p-value is smaller than 2.2e-16).
The proportion of transplants paid for by the disability in-
surance scheme (IV) remained stable. The massive reduction
of transplants for indications with “no” is in part explained by
a change in category, for example, lymphoma or plasma cell
disorders, in part by renouncing certain indications, for exam-
ple, renal cell carcinoma and adherence to the EBMT current
practice guidelines (16).
Example 2: Swiss Spine Registry
A second example of a mandatory registry as condition for
reimbursement is orthopedic implants. Three technologies fell
under the “yes, in evaluation” regime: dynamic spinal stabiliza-
tion (Type Dynesis), dynamic interspinous stabilization (Type
DIAM), and lumbar/cervical discs. The national registry, the
so-called SWISSspine Registry, was established in 2005 at the
Institute for Evaluative Research at the University of Berne and
has collected data on each reported case since then. Collected
items encompass back and leg pain, walking distance, consump-
tion of medication, quality of life, and complications/revisions.
No specific cost data is collected (20). All three technologies
started with an initial evaluation period of 1 year, which was
prolonged by several years in each case. The evaluation is fi-
nanced by the industry, which pays a lump sum per patient of
CHF 100.
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Table 2. Number of Hematopoietic Stem Cell Transplants per Time Period and Reimbursement Category
1997–2001 2002–2007 2008–2011 Total
Reimbursement Category N % N % N % N %
Yes 435 26% 1451 56% 1361 67% 3247 52%
Yes, in evaluation 377 22% 1034 40% 594 29% 2005 32%
No, in evaluation 0 0% 7 0.3% 0 0% 7 0.1%
No 797 47% 42 2% 22 1% 861 14%
Not listed 58 3% 0 0% 0 0% 58 1%
Disability Insurance (IV) 22 1% 38 1% 47 2% 107 2%
Total 1689 2572 2024 6285
Share of Total 27% 41% 32% 100%
The numbers of average annual collected cases were: for
Dynesis 50 cases from six centers, for DIAM 149 cases from
nine centers and for lumbar/cervical discs 233 cases from
twenty-four centers. Results from the registry are regularly pub-
lished (21;22–23). No information is available as to the degree
of participation in the registry for all cases with spine surgery.
DISCUSSION
Conditional coverage for medical technologies has been used
in Switzerland since 1996 and been extended to a total number
of forty-five such decisions of “yes, in evaluation” until 2012.
Numbers were higher in the first 9 years from 1996 to 2004
(31 decisions) than thereafter (14 decisions) but the concept
remains. The reasons for this apparent change are outside of
the scope of this analysis; influencing factors could be a change
in the respective minister, a change in the composition of the
commission (ELGK) that gives the recommendation or exter-
nal factors. The “no, in evaluation” category was abandoned in
2004 due to lack of influence on providers and manufacturers
to generate evidence. It is of interest to note that HSCT for
autoimmune diseases represents an exceptional positive exam-
ple, where the “no, in evaluation” triggered research and led to
prospective controlled studies.
The study clearly shows that the decisions for CED varied
depending on the type of medical technology under scrutiny
with a higher number of “yes, in evaluation” for alternative
medicine, diagnostic procedures and surgical interventions, and
a higher number of “no, in evaluation” for radiological and
medical interventions or transplant procedures. The study also
shows that the time from initial decision to final evaluation
varies widely, independent of numbers of procedures within
the technology to be evaluated or type of category. There is
no obvious argument to maintain an open end for more than
a decade. Again, the reasons for these patterns of decisions
are unknown. The absence of explanations clearly indicates an
urgent need for an evaluation of HTA evaluations.
Strengths and Weaknesses
The strengths of this study are the length of the period of time
it covers and the many very different “non-drug” technologies
under a CED regime as well as the concentration on a single
country with a predefined HTA structure after introduction of a
new law. It is the first systematic evaluation of the duration of
CED decisions and final outcome for each technology. It pro-
vides information on additional criteria such as restrictions to
specific centers, specialists or indications, and indicates where
registries were required. Finally, the study shows data on num-
bers of centers and patients for two selected technologies where
registries had to be kept (HSCT, Spine).
There are some clear limitations of this study. There is no
informationwhatsoever on the reasons for the initial recommen-
dations of the commission leading to “Yes/no, in evaluation” nor
on the reasons for the final decisions “Yes/No.” There is no in-
formation on costs of these evaluations for the service provider,
the health insurer or the registries (where required). There are
no data from other registries, whether successful or not, nor on
the reasons for success or failure. There is no information on
whether the final evaluations were seen as successes or failures
and for what reasons. Finally, there is no information on how
far the ELGK decisions had an impact on treatment patterns in
Switzerland.
CONCLUSIONS
In summary, these data clearly show that CED is a reality in
Switzerland. As such, it did provide access to promising thera-
pies early on for those cases where the final decision became a
“yes”; it made it possible to base the final “no” on more solid
grounds after a field evaluation. The study shows the long time
span required to come to a final decision, providing an additional
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argument to favor CED early on in the course of introducing po-
tentially controversial nondrug technologies. At the same time,
despite a wealth of quantitative data, no information could be
obtained on factors associatedwith final outcome. Clearly, more
studies evaluating HTA decisions are warranted.
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